Vindesine

Role

Indications

Reactions

Secondary

Diffuse Large B-cell Lymphoma	18.3%
Burkitt's Lymphoma	17.1%
Non-hodgkin's Lymphoma	11.9%
Acute Lymphocytic Leukaemia	9.8%
Burkitt's Leukaemia	7.7%
Drug Use For Unknown Indication	6.8%
Hodgkin's Disease	4.6%
B-cell Lymphoma	3.4%
Leukaemia	3.0%
Haematological Malignancy	2.9%
Prophylaxis	2.8%
Stomatitis	1.7%
B Precursor Type Acute Leukaemia	1.6%
Langerhans' Cell Granulomatosis	1.6%
Lymphoma	1.4%
Central Nervous System Lymphoma	1.3%
Nervous System Disorder	1.2%
Multiple Myeloma	1.0%
Acute Myeloid Leukaemia	1.0%
Adult T-cell Lymphoma/leukaemia	1.0%

Toxicity To Various Agents	9.3%
Febrile Neutropenia	8.3%
Stomatitis	8.3%
Death	7.4%
Sepsis	7.4%
Mucosal Inflammation	6.5%
Off Label Use	5.6%
Pneumonia	5.6%
Acute Promyelocytic Leukaemia	4.6%
Nephropathy Toxic	4.6%
Anaemia	3.7%
Hepatotoxicity	3.7%
Pneumocystis Jiroveci Pneumonia	3.7%
Pyrexia	3.7%
Thrombocytopenia	3.7%
Bacterial Sepsis	2.8%
Drug Toxicity	2.8%
Febrile Bone Marrow Aplasia	2.8%
Precursor T-lymphoblastic Lymphoma/leukaemia	2.8%
Systemic Candida	2.8%

Concomitant

Product Used For Unknown Indication	17.3%
Diffuse Large B-cell Lymphoma	13.8%
Chemotherapy	11.5%
Non-hodgkin's Lymphoma	9.3%
Acute Lymphocytic Leukaemia	8.8%
T-cell Lymphoma	7.0%
Drug Use For Unknown Indication	5.5%
Burkitt's Lymphoma	5.0%
Non-hodgkin's Lymphoma Metastatic	3.0%
Prophylaxis Of Nausea And Vomiting	2.8%
Diffuse Large B-cell Lymphoma Stage Iv	2.5%
Adult T-cell Lymphoma/leukaemia	2.0%
Lymphoma	1.8%
Multiple Myeloma	1.8%
Prophylaxis Against Graft Versus Host Disease	1.8%
Precursor T-lymphoblastic Lymphoma/leukaemia	1.5%
Asthma	1.3%
Hodgkin's Disease	1.3%
Precursor B-lymphoblastic Lymphoma	1.3%
Central Nervous System Lymphoma	1.0%

Pyrexia	10.9%
Febrile Bone Marrow Aplasia	6.5%
Lung Infection	6.5%
Progressive Multifocal Leukoencephalopathy	6.5%
Toxic Skin Eruption	6.5%
Urinary Incontinence	6.5%
Agranulocytosis	4.3%
Gastrointestinal Haemorrhage	4.3%
Graft Versus Host Disease	4.3%
Hepatic Function Abnormal	4.3%
Neutrophil Count Increased	4.3%
Paraesthesia	4.3%
Rash	4.3%
Tongue Disorder	4.3%
Tumour Lysis Syndrome	4.3%
Vision Blurred	4.3%
Vomiting	4.3%
Weight Increased	4.3%
Acute Lymphocytic Leukaemia	2.2%
Acute Myelomonocytic Leukaemia	2.2%

Interacting

Acute Lymphocytic Leukaemia	50.0%
Antifungal Prophylaxis	16.7%
Drug Use For Unknown Indication	16.7%
Lung Infection	16.7%

Neurotoxicity	100.0%